Showing results (81-90 of 470) with videos related to

Sort By:
Pageof 47
The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.
The Lancet. Rheumatology|January 31, 2024
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to knowAngelina Marinkovic, Leslie N Zypchen, Jonathan Chan, et al.
The Lancet. Rheumatology|January 30, 2024
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trialMichelle L M Mulder, Johanna E Vriezekolk, Tamara W van Hal, et al.
The Lancet. Rheumatology|January 30, 2024
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort studyChristoph Kessel, Ndate Fall, Alexei Grom, et al.
The Lancet. Rheumatology|January 24, 2024
The crisis of inadequate treatment in osteoporosisChristian Roux, Karine Briot
The Lancet. Rheumatology|January 24, 2024
Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort studyAjinkya Pawar, Rishi J Desai, Nileesa Gautam, et al.
The Lancet. Rheumatology|January 24, 2024
The future of treatment in systemic sclerosis: can we design better trials?Janet E Pope
The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trialSatoshi Ebata, Ayumi Yoshizaki, Koji Oba, et al.
The Lancet. Rheumatology|January 24, 2024
Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology StudyDonavon Sandoval-Heglund, Eric Roberts, Joonsuk Park, et al.
The Lancet. Rheumatology|January 24, 2024
Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trialAnna Redl, Konstantin Doberer, Luisa Unterluggauer, et al.
Pageof 47